A retrospective review of outcomes after hyperbaric oxygen therapy for the treatment of calciphylaxis.

HBOT IV STS calciphylaxis hyperbaric oxygen therapy intravenous sodium thiosulfate nephrogenic calciphylaxis non-nephrogenic calciphylaxis wound healing

Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 07 11 2022
revised: 13 06 2023
accepted: 02 07 2023
pubmed: 17 8 2023
medline: 17 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

Calciphylaxis is a thrombotic vasculopathy characterized by painful necrotic ulcerations. There are no Food and Drug Administration approved therapies despite high mortality. To compare mortality and wound healing outcomes in patients treated with hyperbaric oxygen therapy (HBOT) in addition to intravenous sodium thiosulfate (IV STS) versus patients who received IV STS only. Findings were stratified by dialysis status and modality. 93 patients were included, with 57 patients in the control group (IV STS) and 36 patients in the treatment group (HBOT + IV STS). Mortality data were analyzed with traditional survival analyses and Cox proportional hazard models. Longitudinal wound outcomes were analyzed with mixed effects modeling. Univariate survival analyses showed that full HBOT treatment was associated with significantly (P = .016) longer survival time. Increasing number of HBOT sessions was associated with improved mortality outcomes, with 1, 5, 10 and 20 sessions yielding decreasing hazard ratios. There was also a significant (P = .042) positive association between increasing number of HBOT sessions and increased wound score. Data collection was retrospective. HBOT may have a role in the treatment of calciphylaxis with benefits demonstrated in both mortality and wound healing. Larger prospective studies are needed to identify which patients would most benefit from this intervention.

Sections du résumé

BACKGROUND BACKGROUND
Calciphylaxis is a thrombotic vasculopathy characterized by painful necrotic ulcerations. There are no Food and Drug Administration approved therapies despite high mortality.
OBJECTIVE OBJECTIVE
To compare mortality and wound healing outcomes in patients treated with hyperbaric oxygen therapy (HBOT) in addition to intravenous sodium thiosulfate (IV STS) versus patients who received IV STS only. Findings were stratified by dialysis status and modality.
METHODS METHODS
93 patients were included, with 57 patients in the control group (IV STS) and 36 patients in the treatment group (HBOT + IV STS). Mortality data were analyzed with traditional survival analyses and Cox proportional hazard models. Longitudinal wound outcomes were analyzed with mixed effects modeling.
RESULTS RESULTS
Univariate survival analyses showed that full HBOT treatment was associated with significantly (P = .016) longer survival time. Increasing number of HBOT sessions was associated with improved mortality outcomes, with 1, 5, 10 and 20 sessions yielding decreasing hazard ratios. There was also a significant (P = .042) positive association between increasing number of HBOT sessions and increased wound score.
LIMITATIONS CONCLUSIONS
Data collection was retrospective.
CONCLUSION CONCLUSIONS
HBOT may have a role in the treatment of calciphylaxis with benefits demonstrated in both mortality and wound healing. Larger prospective studies are needed to identify which patients would most benefit from this intervention.

Identifiants

pubmed: 37586460
pii: S0190-9622(23)02495-7
doi: 10.1016/j.jaad.2023.07.1031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-51

Informations de copyright

Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest None disclosed.

Auteurs

Bianca Biglione (B)

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

Bethany Cucka (B)

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

Christopher Iriarte (C)

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Joseph J Locascio (JJ)

Harvard Medical School, Boston, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

Jeremy W Goldfarb (JW)

Harvard Medical School, Boston, Massachusetts; Department of Anesthesia, Massachusetts Eye and Ear Infirmary, Boston Massachusetts.

Adina Gutium (A)

Department of Internal Medicine, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.

Xinaida T Lima (XT)

Clinical Unit for Research Trials and Outcomes in Skin (CURTIS), Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Federal University of Ceará, Fortaleza, Brazil.

Daniela Kroshinsky (D)

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: dkroshinsky@mgh.harvard.edu.

Classifications MeSH